SEC Form 4 · accession 0001179110-15-012678
GILEAD SCIENCES, INC. · GILD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John C Martin
Officer — Chairman and CEO · Director
Period of report
Aug 21, 2015
Accepted (ET)
Aug 26, 2015 · 5:51 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000882095
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 21, 2015 | G | 133,213 | $0.00 | D | 4,081,279 | D | |
| Common StockF1 | Aug 24, 2015 | G | 133,213 | $0.00 | D | 3,948,066 | D | |
| Common Stock | Aug 24, 2015 | A | 133,213 | $0.00 | A | 133,213 | I | by Trust |
| Common StockF2 | Aug 25, 2015 | S | 59,800 | $104.3258 | D | 73,413 | I | by Trust |
| Common StockF3 | Aug 25, 2015 | S | 56,613 | $105.679 | D | 16,800 | I | by Trust |
| Common StockF4 | Aug 25, 2015 | S | 16,800 | $106.4514 | D | 0 | I | by Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares gifted to charitable trust
- F2Sale prices reported for the transactions reported here range from $104.17 to $105.13. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F3Sale prices reported for the transactions reported here range from $105.20 to $106.19. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.
- F4Sale prices reported for the transactions reported here range from $106.23 to $106.73. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request.